Repatha cut by 20 percent the combined risk of having either a heart attack, stroke or a heart-related death. That happened to nearly 6 percent of people on Repatha versus more than 7 percent on the dummy drug. The benefit grew with longer use, and was 25 percent the second year, said Sabatine, who consults for Amgen and other drugmakers. The drug cut by 15 percent a broader set of problems — the ones above plus hospitalization for chest pain or an artery-opening procedure. Nearly 10 percent of folks on Repatha had one versus more than 11 percent on the...